N-烷基/芳基-N′-(4-芳基噻唑-2-基)-N"-糖基胍的合成及生物活性研究

2,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖基异硫氰酸酯(1)与2-氨基-4-取代苯基噻唑(2a～2b)反应,生成糖基硫脲衍生物3a～3b,再在伯胺存在下经氯化汞脱硫,得到一系列新的N-烷基/芳基-N′-(4-芳基噻唑-2-基)-N″-糖基胍类化合物(4a～4e,5a～5e).所有新化合物的结构均经IR,1H NMR,MS谱和元素分析证实,所得产物均为β-构型.生物活性测试结果表明,化合物4b和5d对HIV-1 PR表现出了较高的抑制活性.     

6-取代氨基-2-烷硫基腺苷化合物的合成及抗血小板凝聚活性

以鸟苷(1)为原料, 经过糖环保护得到2',3',5'-三-O-乙酰基鸟嘌呤核苷(2), 化合物2与三氯氧磷反应得到2-氨基-6-氯-9-(2',3',5'-三-O-乙酰基-β-D-呋喃核糖基)嘌呤(3), 化合物3经重氮化后再与二烷基二硫醚反应得到2-烷硫基-6-氯-9-(2',3',5'-三-O-乙酰基-β-D-呋喃核糖基)嘌呤(4a~4d), 化合物4a~4d与胺进行亲核取代反应后, 脱去糖环保护得到12个新型的6-取代氨基-2-烷硫基腺苷化合物(5a~5l). 采用¹H NMR, ¹³C NMR, IR和高分辨质谱(HRMS)对目标化合物的结构进行了确证, 并对所有化合物进行了体外抗血小板聚集活性测试. 结果表明, 当测试浓度为10 μmol/L时, 化合物5a~5l仍具有一定的抗凝活性, 其中, 6-(3-苯基丙基)氨基-2-丙硫基腺苷(5d)活性最为显著, 抑制率可达90.2%.     

5-甲基-1,2,4-三唑-3-硫酮类糖苷化合物的合成及抗菌活性

在KOH/丙酮体系中, 以5-甲基-4-N-取代苯基亚胺/胺基-1,2,4-三唑-3-硫酮为原料, 与溴-α-D-四乙酰葡萄糖进行Kenigs-Knorr反应合成了10个新颖的化合物—5-甲基-4-N-取代苯基亚胺基/胺基-3-S-(2',3',4',6'-四-O-乙酰基-β-D-吡喃葡萄糖基)-1,2,4-三唑(2a~2e, 5a~5e); 并在二氯甲烷/甲醇/甲醇钠混合体系中水解脱除乙酰基, 得到10个新颖的化合物—5-甲基-4-N-取代苯基亚胺基-3-S-(β-D-吡喃葡萄糖基)-1,2,4-三唑(3a~3e)及5-甲基-4-N-取代苯基胺基-3-S-(β-D-吡喃葡萄糖基)-1,2,4-三唑(6a~6e). 化合物的结构均经核磁共振波谱(NMR)、 红外光谱(IR)和高分辨质谱(HRMS)分析确证. 生物活性测试结果表明, 目标化合物对大肠杆菌、 金黄色葡萄球菌、 枯草芽孢杆菌和白色念珠球菌普遍具有较好的抗菌活性. 化合物3d和3e对4种菌株的最小抑菌浓度相对较低, 表现出较强的广谱抗菌活性.     

含吡啶组块3-脂肪基-1, 2, 4-三唑并[3,4-b]-1,3,4噻二唑衍生物的合成及生物活性

分别将6种脂肪酸与二氨基硫脲反应,合成了6种含不同碳数的3-脂肪基-1,2,4-三唑(1a~1f),其中化合物1e和1f为首次合成。在三氯氧磷存在下,分别将化合物1a~1f与4-吡啶甲酸和2,6-吡啶二甲酸反应,首次高产率合成了12种三唑并噻二唑衍生物(2a~2f)和(3a~3f)。为对比引入3-脂肪基和吡啶组块对生物活性的影响,分别合成了3-苯基含吡啶组块产物(5)、双枝3-苯基含吡啶组块化合物(6)、不含吡啶组块的化合物(7a~7c)和(8a~8c)。应用IR、1H NMR和HRMS等技术手段对19种新物质进行了结构表征,并研究了其对Cdc25B和PTP1B的抑制性能,研究结果表明,含有吡啶组块的双枝脂肪基化合物3b、3d、3e和3f对Cdc25B有良好的抑制活性,IC50值(mg/L)分别为1.12±0.27、2.72±1.07、0.72±0.05和4.97±0.93;化合物2b、3d和5对PTP1B表现出较高的抑制活性,IC50值(mg/L)分别为0.98±0.13、1.33±0.11和2.18±0.20。     

新型1,2,3-三唑类化合物的合成及抗菌构效关系

根据活性基团拼接原理, 以4-取代-苯胺为原料, 经重氮化、 关环和缩合反应合成了17个化合物1-(4-取代苯基)-5-取代苯基亚氨基-4-取代-1,2,3-三唑(7a~7c和13a~13d)和1-(4-取代苯基)-5-取代苄基氨基-4-取代-1,2,3-三唑(5a~5c, 10a~10c和14a~14d), 其中化合物5a~5c, 7b, 7c, 10a, 10c, 13b~13d和14b~14c为新化合物, 对所制备化合物的结构进行了表征. 生物活性测试结果表明, 所有化合物均表现出一定的抑菌活性, 对大肠杆菌的抑菌活性均优于氟康唑; 化合物7a和10c对金黄色葡萄球菌的抑制活性明显优于氟康唑; 而化合物13a和13d则对白色念球菌表现出良好的抑制活性, 与三氯生相当.     

2-(2,2-二甲基-2,3-二氢苯并呋喃-5-基)-2-(1,2,4-三唑-1-甲基)-1,3-二氧戊环的合成与杀菌活性

以对羟基苯乙酮为原料,经醚化、Claisen重排、环合得2,2-二甲基-5-乙酰基-2,3-二氢苯并呋喃(4a).2,2-二甲基-5-乙酰基-2,3-二氢苯并呋喃(4a~4c)经卤代、缩酮化、取代反应得12种2-(2,2-二甲基-2,3-二氢苯并呋喃-5-基)-2-(1,2,4-三唑-1-甲基)-1,3-二氧戊环(1a~1l).化合物经NMR,元素分析等确证结构,并测试了其对7种植物病菌的抑制活性,结果显示化合物1a,1b,1e,1f,1g和1l对油菜菌核病菌的抑制率均大于70%(25 mg/L),化合物1a和1b对小麦白粉病菌杀灭活性较好,抑制率均为80.0%(500 mg/L).     

新型1,2,4-三氮唑类化合物的合成及其杀菌活性

以α-乙酰基-γ-丁内酯为原料,经亲核取代、开环、闭环和亲核取代反应制得1-氯-1-氯乙酰基环丙烷（5); 5与1,2,4-三氮唑反应制得1-三唑基乙酰-1-氯代环丙烷(6); 6与一系列卤代化合物进行亲核取代反应制得6个新化合物(7a~7f); 7a~7f经还原反应合成了6个新型的1,2,4 三氮唑类化合物(8a~8f),其结构经¹H NMR, ¹³C NMR, LC-MS和元素分析表征。采用生长速率法研究了化合物的杀菌活性。结果表明：用药量为50 μg·mL^-1时,化合物8f对立枯丝核菌和禾谷镰孢菌的抑制率分别为56.8%和43.8%,化合物8e对黄瓜枯萎病菌的抑制率为57.9%。     

新型吡咯并三嗪酮类PARP-1抑制剂的设计、合成及生物活性

分别以5-溴-2-氟苯甲腈(1a)和3-溴苯甲腈(1b)为原料,经Sonogashira偶联,脱三甲基硅基保护基,三分子偶联及水解等5步反应制得中间体2-氟-5-［(4-氧代-3,4-二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］苯甲酸（6a)和3-[(4-氧代-3,4-二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］苯甲酸（6b）。环烷基甲酸经酰氯化,缩合和脱Boc保护基3步反应制得环烷基哌嗪-1-基甲酮(7a~7c)。 6a与NCS（1 eq.）反应制得5-［(6-氯-4氧代-3,4二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］-2氟 苯甲酸(6c); 6a与NCS(2 eq.)反应制得5-［(6,7-二氯-4氧代-3,4二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］-2氟-苯甲酸(6d)。 6a~6d, 6a~6c分别与7a~7c和1-（2-嘧啶基）哌嗪在TBTU（缩合剂）,DIPEA（碱）的作用下合成了13个新型吡咯并三嗪酮类PARP-1抑制剂(8a~8m),其结构经¹HNMR和MS(ESI)表征。采用Alarm blue法研究了8a~8m对肿瘤细胞MDA-MB-436的抑制活性(IC₅₀)。结果表明：8f, 8g, 8i和8j对MDA-MB-436有较强的抑制活性（IC₅₀=30.5~69.3 nmol·L^-1）。     

伊马替尼衍生物的合成及细胞毒活性研究

以3-乙酰基嘧啶、2-甲基-5-硝基苯胺为起始原料,经加成、缩合、环化、还原得到中间体伊马替胺(6),再与异氰酸酯和芳酰基异硫氰酸酯胺解得到脲类(7a~7e)和芳酰基硫脲类(8a~8g)共12个化合物。目标化合物经过IR、1H NMR、13C NMR、HRMS等结构确证。采用四甲基偶氮唑盐(MTT)法考察目标化合物细胞毒活性,结果显示,目标化合物对所选肿瘤细胞的增殖活性具有一定抑制作用,其中化合物7d、7e、8d对人白血病细胞(K562)和人肝癌细胞(Hep G2)的抑制活性接近伊马替尼。     

胍基木吡喃糖苷的合成及其抗HIV蛋白酶活性

2,3,4-三-O-乙酰基-b-D-木吡喃糖基异硫氰酸酯1与2-氨基-4/6-取代-苯并噻唑2a～2e反应, 生成糖基硫脲衍生物3a～3e, 再在伯胺存在下经氯化汞脱硫, 得到一系列新的胍基木吡喃糖苷类化合物4a～4e, 5a～5e, 6a～6e, 7a～7e, 所有新化合物的结构均经IR, ¹H NMR, MS谱和元素分析证实, 所得产物均为β-构型. 生物活性测试结果表明, 化合物4c, 5b, 6b～6d, 7b等对HIV-1蛋白酶表现出了较高的抑制活性.     

Synthesis and Antimicrobial Studies of Novel Imidazole Containing Bisazetidinones and Bisthiazolidinone Derivatives

A simple, practical, and efficient approach to new series of imidazole containing bisazetidinones ( 7a , 7b , 7c , 7d , 7e , 7f , 7g , 7h , 7i , 7j and 9a , 9b , 9c , 9d , 9e , 9f , 9g , 9h , 9i , 9j ) was prepared by Staudinger [2 + 2] cycloaddition reaction, and bisthiazolidinones ( 8a , 8b , 8c , 8d , 8e , 8f , 8g , 8h , 8i , 8j and 10a , 10b , 10c , 10d , 10e , 10f , 10g , 10h , 10i , 10j ) were obtained by cyclization of bisimines with thioglycolic acid. The bisimines ( 5a , 5b , 5c , 5d , 5e , 5f , 5g , 5h , 5i , 5j and 6a , 6b , 6c , 6d , 6e , 6f , 6g , 6h , 6i , 6j ) were synthesized by the condensation of 3‐(1‐(3‐aminobenzyl)‐4, 5‐dihydro‐1H‐imidazol‐2‐yl) aniline ( 3 , 4 ) with a series of different substituted aromatic aldehydes. All the newly synthesized target compounds were evaluated for their in vitro antimicrobial activity against two Gram‐positive bacteria and two Gram‐negative bacteria. Additionally, these synthesized compounds were tested for their antifungal activities. Few compounds showed very good antibacterial and antifungal activity.     

The Utility of Carbon Disulphide and Lawesson's Reagent for Synthesis of Different Fused Heterocycles for Antimicrobial Evaluation

Hexahydroquinolines 1a , 1b reacted with carbon disulphide in different conditions to yield the corresponding adducts 2a , 2b and 3a , 3b . Carrying out the same reactions in acetone as solvent produced the modified new products 4a , 4b . The interaction of pyrazolopyridine derivatives 5a , 5b , 5c , 5d with carbon disulphide under the same previous conditions furnished the isolated products 6a , 6b , 6c , 6d , 7a , 7b , 7c , 7d , and 8a , 8b , 8c , 8d . Studying the behavior of 1a , 1b or 5a , 5b , 5c , 5d toward Lawesson's reagent (LR) formed the final adducts 11a , 11b or 12a , 12b , 12c , 12d . The structure of synthesized compounds was confirmed with the spectroscopic and microanalytical data. The biological activities of 2a , 4a , 4b , 7a , 7c , 8d , 11a , 11b , 12b , and 12c were tested for antimicrobial evaluation.     

Synthesis of furo[3,2-g]chromones under microwave irradiation and their antitumor activity evaluation

A series of furo[3,2-g]chromone derivatives were synthesized via the reaction of furochromone carbaldehyde 1 with amines 3a - d and thioglycolic acid to give thiazolidinones 4a - d . The later react with benzaldehyde/thiourea or hydroxylamine and DMF-DMA in glacial acetic acid to give thiazolopyrimidines 5a - d or thiazoloisoxazoles 6a - d , respectively. Also, the synthesis of α-aminophosphonates via the one-pot reaction of 1 and amines 3a , b were trapped by dialkylphosphites 7a - c afforded the corresponding α-aminophosphonates 8a - f . Applying hexaalkyltriamidophosphites 9a , b to 1 gives alkylidenephosphorane ylides 11a , b in an open structure form. In the present investigation, the in vitro inhibition capacity of compounds ( 4a , 4c , 5b , 5c , 6b - d , 8a - f , and 11a ) was screened in three human cancer cell lines HCT-116, MCF-7, and HepG2. The anticancer activity results revealed that 8b and 8e had more potent cytotoxic inhibition activity against HCT-116 cell line; however, all the tested compounds had obviously less cytotoxic activity against MCF-7 cell line, while 5b , 5c , and 6d were potent against HepG2 cell line compared with that of doxorubicin.     

New chemistry of olefin complexes of platinum(II) unravelled by basic conditions: synthesis and properties of elusive cationic species

The evolution in basic medium ([RO-] = 1 M in methanol, R = H or Me) of five-coordinate platinum(II) compounds, [PtCl2(eta2-C2H4)(N-N)], 2a-c, (N-N = N,N,N',N'-tetramethyl-1,2-ethanediamine, a; 2,2'-bipyridyl, b; 1,10-phenanthroline, c) leads to the formation of [PtCl(eta1-CH2CH2-OCH3)(N-N)], 5a-c. The analogous compound 5d (N-N = 2,9-dimethyl-1,10-phenanthroline, d) can also be prepared, but not via transformation of the five-coordinate species 2d in basic medium where it is quite stable. 5d can instead be prepared by reaction of d with a strongly basic methanol solution of Zeise's anion [PtCl3(eta2-C2H4)](-), 1. In such a medium the di-anionic trans-[PtCl2(OR)(eta1-CH2CH2-OCH3)](2-) species (1") reacts with to form exclusively 5d. Hydrolysis of with acids bearing weakly coordinating anions leads to [PtCl(eta2-C2H4)(N-N)]+, 3a-c, as stable cations; upon the same treatment 5d does not generate 3d, but it reacts with HCl to give 2d in almost quantitative yield. Cationic complexes 3b, 3c, here reported for the first time, were reacted with some nucleophiles and their behaviour compared with that of the already known 3a. In 3b, 3c the metal centre competes with the coordinated ethene for binding to nucleophiles; therefore the acetylacetonate anion can either add to the olefin (affording compounds 6b, 6c ) or to the metal ion replacing the ethene ligand (yielding compounds 7b, 7c). Under similar conditions, 3a gives exclusively 6a. Secondary amines readily add to ethene in 3b, 3c, affording the addition products 8b, 8c, which undergo a ready cyclization to an azaplatinacyclobutane ring (9b, 9c). The remarkable ease of the four-membered ring formation has been related to the high electrophilic character of the metal core in 3b, 3c.     

Synthesis,Anti‐Microbial,and Cytotoxic Activities Evaluation of Some New Pyrido[2,3‐d]Pyrimidines

Novel pyridine derivatives 1d and 7 , pyrido[2,3‐d]pyrimidine derivatives 2a , 2b , 2c , 2d , 3a , 3b , 3c , 3d , 4a , 4b , 4c , 4d , 5a , 5b , 5c , 5d , 6a , 6b , 6c , 6d , 8a , 8b , and 9a , 9b were synthesized and screened for their anti‐microbial and cytotoxic activities. Compounds 2b , 2c , 3b , 3c , 5b , 5c , 6b , 6c , and 7 showed excellent anti‐microbial activities against all the tested bacteria and fungi compared to the reference drugs. Furthermore, they exhibited high safety profile in cytotoxicity test except 2c and 3c . The structures of the newly synthesized compounds were confirmed by spectral data and elemental analysis.     

氧化剂存在下吡啶叶立德与1,4,4a,8a-四氢-1,4-桥亚甲基萘-5,8-二酮的反应

在[(Py)4Co(HCrO₄)₂]存在下,吡啶叶立德、喹啉叶立德或异喹啉叶立德分别和1,4,4a,8a-四氢-1,4-桥亚甲基萘-5,8-二酮反应,一步法合成了中氮茚类多环化合物(1a～1c,2a～2b,3).该方法原料易得,反应条件容易控制,为合成这类化合物提供了新方法.     

C-F or C-H bond activation and C-C coupling reactions of fluorinated pyridines at rhodium: synthesis, structure and reactivity of a variety of tetrafluoropyridyl complexes

Reactions of [RhH(PEt3)3] (1) or [RhH(PEt3)4] (2) with pentafluoropyridine or 2,3,5,6-tetrafluoropyridine afford the activation product [Rh(4-C5NF4)(PEt3)3] (3). Treatment of 3 with CO, 13CO or CNtBu effects the formation of trans-[Rh(4-C5NF4)(CO)(PEt3)2] (4a), trans-[Rh(4-C5NF4)(13CO)(PEt3)2] (4b) and trans-[Rh(4-C5NF4)(CNtBu)(PEt3)2] (5). The rhodium(III) compounds trans-[RhI(CH3)(4-C5NF4)(PEt3)2] (6a) and trans-[RhI(13CH3)(4-C5NF4)(PEt3)2] (6b) are accessible on reaction of 3 with CH3I or 13CH3I. In the presence of CO or 13CO these complexes convert into trans-[RhI(CH3)(4-C5NF4)(CO)(PEt3)2] (7a), trans-[RhI(13CH3)(4-C5NF4)(CO)(PEt3)2] (7b) and trans-[RhI(13CH3)(4-C5NF4)(13CO)(PEt3)2] (7c). The trans arrangement of the carbonyl and methyl ligand in 7a-7c has been confirmed by the 13C-13C coupling constant in the 13C NMR spectrum of 7c. A reaction of 4a or 4b with CH3I or 13CH3I yields the acyl compounds trans-[RhI(COCH3)(4-C5NF4)(PEt3)2] (8a) and trans-[RhI(13CO13CH3)(4-C5NF4)(PEt3)2] (8b), respectively. Complex 8a slowly reacts with more CH3I to give [PEt3Me][Rh(I)2(COCH3)(4-C5NF4)(PEt3)](9). On heating a solution of 7a, the complex trans-[RhI(CO)(PEt3)2] (10) and the C-C coupled product 4-methyltetrafluoropyridine (11) have been obtained. Complex 8a also forms 10 at elevated temperatures in the presence of CO together with the new ketone 4-acetyltetrafluoropyridine (12). The structures of the complexes 3, 4a, 5, 6a, 8a and 9 have been determined by X-ray crystallography. 19F-1H HMQC NMR solution spectra of 6a and 8a reveal a close contact of the methyl groups in the phosphine to the methyl or acyl ligand bound at rhodium.     

Synthesis of Novel Benzofuran‐Gathered C‐2,4,6‐substituted Pyrimidine Derivatives Conjugated by Sulfonyl Chlorides: Orally Bioavailable,Selective, Effective Antioxidants and Antimicrobials Drug Candidates

In the present study, we have made an effort to develop the novel synthetic antioxidants and antimicrobials with improved potency. The novel benzofuran‐gathered C‐2,4,6‐substituted pyrimidine derivatives 5a , 5b , 5c , 5d , 5e , 5f , 6a , 6b , 6c , 6d , 6e , 6f , 7a , 7b , 7c , 7d , 7e , 7f , 8a , 8b , 8c , 8d , 8e , 8f , 9a , 9b , 9c , 9d , 9e , 9f were synthesized by simple and efficient four‐step reaction pathway. Initially, o‐alkyl derivative of salicylaldehyde readily furnish corresponding 2‐acetyl benzofuran 2 in good yield, upon the treatment with potassium tertiary butoxide in the presence of molecular sieves. Further, Claisen–Schmidt condensation with aromatic aldehydes via treatment with thiourea followed by coupling reaction with different sulfonyl chlorides afforded target compounds. The structures of newly synthesized compounds were confirmed by IR, ¹H NMR, ¹³C NMR, mass, and elemental analysis and further screened for their antioxidant and antimicrobial activities. The results showed that the synthesized compounds 8b , 8e , 9b , and 9e produced significant antioxidant activity with 50% inhibitory concentration higher than that of reference, whereas compounds 7d and 7c produced dominant antimicrobial activity at concentrations 1.0 and 0.5 mg/mL compared with standard Gentamicin and Nystatin, respectively.     

Blue-luminescent/electroluminescent Zn(II) compounds of 7-azaindole and N-(2-pyridyl)-7-azaindole: Zn(7-azaindole)2(CH3COO)2, Zn(NPA)(CH3COO)2, and Zn(NPA)((S)-(+)-CH3CH2CH(CH3)COO)2 (NPA = N-(2-pyridyl)-7-azaindole)

A new 7-azaindole zinc(II) compound, Zn(7-azaindole)2(CH3COO)2 (1), a new ligand N-(2-pyridyl)-7-azaindole (NPA), and two NPA zinc(II) complexes, Zn(NPA)(CH3COO)2 (2) and Zn(NPA)((S)-(+)-CH3CH2CH(CH3)COO)2 (3), have been synthesized and structurally characterized. Compound 1 has a tetrahedral geometry, whereas compounds 2 and 3 have irregular six-coordinate geometry. The NPA ligand in compounds 2 and 3 functions as a bidentate chelate to the zinc center. Compound 1 has a blue luminescence in the solution and the solid state. Compounds 2 and 3 emit a blue color in the solid state. In solution, compounds 2 and 3 are fluxional, as established by 1H NMR experiments. Compound 1 is thermally stable, whereas compounds 2 and 3 undergo decomposition when heated in the solid state. A blue electroluminescent device using compound 1 as the emitting layer has been fabricated. Crystal data: NPA, monoclinic, P2(1)/c, a = 13.993(5) A, b = 8.456(3) A, c = 16.886(5) A, beta = 104.666(12) degrees, V = 1932.9(11) A3; 1, triclinic, P1, a = 9.5114(18) A, b = 10.460(7) A, c = 11.002(3) A, alpha = 117.18(3) degrees, beta = 103.287(18) degrees, gamma = 90.94(2) degrees, V = 938.3(7) A3; 2, monoclinic, C2/c, a = 13.234(6) A, b = 9.373(3) A, c = 13.956(7) A, beta = 113.24(3) degrees, V = 1590.7(12) A3; 3, monoclinic, P2(1), a = 11.047(7) A, b = 15.343(9) A, c = 13.785(8) A, beta = 100.123(9) degrees, V = 2300(2) A3.     

Pyrazoles and pyrazolo[4,3‐e]pyrrolo[1,2‐a]pyrazines II

Synthesis of the title compounds was achieved using the anils 2a , 2b , 2c , 2d , 2e and 5a , 5b , 5c derived from the 4‐aminopyrazole 1 as starting materials. These compounds were allowed to react with mercaptoacetic acid in boiling dry benzene to afford the corresponding thiazolidinones and spiro‐thiazolidinones 3a , 3b , 3c , 3d , 3e and 6a , 6b , 6c , respectively. Pictet—Spengler reaction of the 4‐aminopyrazole hydrochloride 7 with aromatic aldehydes and cyclic ketones resulted in the formation of new pyrazolo[4,3‐e]pyrrolo[1,2‐a]pyrazines 8a , 8b , 8c , 8d , 8e and 9a , 9b , respectively. Other derivatives of pyrazolo pyrrolopyrazines 10 and 11 were obtained via the reaction of the amino derivative 1 with 1,1′‐carbonyldiimidazol and CS₂, respectively. J. Heterocyclic Chem., (2011).